National Institutes of Health Workshop to Accelerate Therapeutic Innovation by Optimizing Kidney Precision Medicine Clinical Trials
- 17 February 2026
- journal article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (11) , 2041-2050
Abstract
The National Institute of Diabetes and Digestive and Kidney Diseases sponsored a scientific workshop in 2024, titled “Preparing for Kidney Precision Medicine Clinical Trials.” The purpose of the workshop was to gain a better understanding of the therapeutic journey of patients with kidney disease and define candidate indicators for precision medicine strategies, targets, and trial readiness. Workshop participants were tasked with identifying best practices, opportunities, and barriers to kidney precision medicine clinical trials, with a shared goal to optimize the design and conduct of these trials. The patient perspective served as a foundation for the meeting. Trial design should be flexible, dynamic, responsive to transitions in patient care and minimize fragmentation of care. The value of understanding mechanisms and defining endophenotypes and targets to facilitate new therapeutic approaches was discussed with examples presented for acute and CKDs. The importance of biomarkers for diagnosis and evaluation of therapeutic response was emphasized. Laboratory and assay considerations for precision medicine trials were discussed with examples of successful large precision medicine trials supported by laboratory networks presented. There was discussion of the barriers to precision trials in nephrology, including suboptimal patient engagement, precision trial expertise, infrastructure, and financial resources. Engagement in demonstration projects to test the ability of various approaches to expedite the right treatment to the right patient was highlighted. Of utmost importance is the better design of clinical trials which consider differences in genetics and status of disease mechanisms to validate individual patient-focused innovative and effective precision therapeutic approaches.Keywords
This publication has 65 references indexed in Scilit:
- From RAAS blockade to regenerative medicine: evolving treatment strategies in Alport syndromePediatric Nephrology, 2025
- Use of Clinical Trial Characteristics to Estimate Costs of New Drug DevelopmentJAMA Network Open, 2025
- PCSK9 Inhibitors: The Evolving FutureHealth Science Reports, 2024
- Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapiesCancer Cell, 2022
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerAnnals of Oncology, 2021
- Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic ExposureJAMA Psychiatry, 2021
- Post–Acute Kidney Injury Proteinuria and Subsequent Kidney Disease ProgressionJAMA Internal Medicine, 2020
- Identification and validation of biomarkers of persistent acute kidney injury: the RUBY studyIntensive Care Medicine, 2020
- I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast CancerCurrent Breast Cancer Reports, 2019
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 UpdateClinical Pharmacology & Therapeutics, 2017